

17 Sep 2021

Bristol-Myers Squibb International Corporation

Email: Clinical.Trials@bms.com

Chaussée de la Hulpe 185

Brussels, Belgium

1170

EudraCT Number:2013-002291-41

Sponsor Protocol Number: CC-486-MEL-001

A Randomized, Open Label, Multi-Center Phase 2 Study of nab-Paclitaxel versus Epigenetic
Modifying Therapy of CC-486 with nab-Paclitaxel in Subjects with Chemotherapy Naïve
Metastatic Melanoma

Trial 2013-002291-41 was withdrawn with 0 patients enrolled. As such no results are reported.